Advertisement
Research ArticleEndocrine and Diabetes

Preclinical Efficacy and Safety of the Novel Anti-diabetic, Anti-obesity MetAP2 Inhibitor, ZGN-1061

Bryan F. Burkey, Niel C. Hoglen, Philip Inskeep, Margaret Wyman, Thomas E. Hughes and James E. Vath
Journal of Pharmacology and Experimental Therapeutics February 28, 2018, jpet.117.246272; DOI: https://doi.org/10.1124/jpet.117.246272
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleEndocrine and Diabetes

Preclinical Efficacy and Safety of the Novel Anti-diabetic, Anti-obesity MetAP2 Inhibitor, ZGN-1061

Bryan F. Burkey, Niel C. Hoglen, Philip Inskeep, Margaret Wyman, Thomas E. Hughes and James E. Vath
Journal of Pharmacology and Experimental Therapeutics February 28, 2018, jpet.117.246272; DOI: https://doi.org/10.1124/jpet.117.246272
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement